RT Journal Article
SR Electronic
T1 629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A1808
OP A1808
DO 10.1136/jitc-2023-SITC2023.0629-C
VO 11
IS Suppl 2
A1 Kim, Tae Min
A1 Ngamphaiboon, Nuttapong
A1 Lee, Ki Hyeong
A1 Desai, Pratibha
A1 Lin, Chia-Chi
A1 Muzaffar, Jameel
A1 Feng, Yin-Hsun
A1 Wu, Shang-Yin
A1 Brahmer, Julie
A1 Chisamore, Michael
A1 Kassner, Paul D
A1 Brockstedt, Dirk G
A1 Goyal, Rakesh Kumar
A1 Nasrah, Nicole
A1 Ho, William
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_2/A1808.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.